A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Diabetic neuropathy (DN) remains a major clinical burden, characterized by progressive sensory dysfunction, pain, and impaired quality of life. Despite the available symptomatic treatments, there is a pressing need for disease-modifying therapies. In…
BACKGROUND: Chronic kidney disease (CKD) affects over half a billion people globally and significantly increases the risk of cardiovascular complications, particularly in those with type 2 diabetes mellitus (T2DM). Although semaglutide, a glucagon-li…
To report a case of a patient undergoing GLP-1 receptor agonist therapy in which increased FDG uptake in brown adipose tissue (BAT) mimicked metastatic head and neck cancer on PET/CT imaging. A 61-year-old female with Class III obesity presented with…
OBJECTIVE: To evaluate the real-world effectiveness of once-weekly semaglutide for weight reduction and change in cardiometabolic risk factors at 24 months in patients with obesity or overweight. METHODS: This real-world retrospective, cohort study u…
Modified glucagon-like peptide 1 (GLP-1) plays a crucial role in type 2 diabetes (T2D) treatment. The comparative hypoglycemic effect among fatty-acid-modified GLP-1 monomer G20, dimer 2G21, and tetramer 4G18 was evaluated in T2D mice. The polymers e…
Loss of lean mass is a potential concern for semaglutide-induced weight loss. This study indicates that semaglutide has unexpected effects on skeletal muscle mass and strength in mice, demonstrating a need to more carefully assess these effects in hu…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide (Wegovy®), are increasingly used for weight management in both adult and pediatric populations. Their mechanism of delayed gastric emptying raises concern for aspiration dur…
IMPORTANCE: Preliminary studies suggest that glucagon-like peptide-1 receptor (GLP-1) agonists, used to treat type 2 diabetes and obesity, may decrease alcohol consumption. OBJECTIVE: To test whether the risk of hospitalization due to alcohol use dis…
Adults with type 1 diabetes (T1D) are increasingly overweight or obese, in part due to intensive insulin therapy. Newer non-insulin medications targeting both hyperglycemia and weight loss are approved for people with type 2 diabetes. These drugs als…
Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardi…
Peripheral surgery evokes neuroimmune activation in the central nervous system and modulates immune cell polarization in the ischemic brain. However, the phenotypic change of microglia and myeloid cells within post-surgical ischemic brain tissue rema…
To determine whether combination therapy (semaglutide + metformin) is more efficacious than monotherapy (metformin alone) in reducing the risk of antipsychotic-induced weight gain (AIWG) in patients with Type 2 Diabetes Mellitus (T2DM). This was a si…
INTRODUCTION: Brain tumors are the most common solid tumors in pediatric oncology. Advances in the treatment of childhood brain tumors have led to increased survival; however, treatment-related morbidity remains high. The risk of developing overweigh…
We evaluated whether drugs approved for other indications that also target metabolic drivers of Alzheimer's disease and related dementia (ADRD) pathogenesis are associated with delayed onset of ADRD. Using routinely collected healthcare data from two…
Initially developed for type 2 diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now emerging as promising candidates for modifying the course of neurodegenerative diseases. This potential stems from the presence of GLP-1…
Prescriptions made for GLP-1 agonists under various brand names (e.g., Ozempic, Wegovy) have more than tripled since 2020. However, research on their use and their side effects at the population level is in its infancy. This study presents descriptiv…
Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose co…